| Ironwood Pharmaceuticals aims to create differentiated, first-in-class medicines that provide relief and clear therapeutic benefits to patients suffering from chronic diseases. We have a commitment to continually evaluate the emerging product profile and market potential of each drug candidate throughout the development process, enabling us to focus our efforts on the most promising candidates.
Linaclotide, our first-in-class compound, is being evaluated in a comprehensive Phase 3 clinical program for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have ongoing efforts to identify product candidates that strengthen our pipeline, including treatments for upper gastrointestinal disorders, pain and inflammation, asthma and allergic disease, and cardiovascular disease.
|
